Kallyope, one of New York’s best funded biotechs, has secured more than $100 million to move two of its programs into the clinic—including its most advanced, an experimental drug designed to treat obesity.
The company was founded in 2015 with $44 million to leverage new learnings about the “gut-brain axis”—pings of communication between our guts and our central nervous system—to make drugs for a range of diseases.
Since then the company has raised $199 million more across two subsequent rounds of funding, including a $112 million Series C financing announced Wednesday, and advanced two programs to the cusp of human testing…. Read more »
UNDERWRITERS AND PARTNERS
